TARO
Income statement / Annual
Last year (2024), Taro Pharmaceutical Industries Ltd.'s total revenue was $629.18 M,
an increase of 9.81% from the previous year.
In 2024, Taro Pharmaceutical Industries Ltd.'s net income was $53.87 M.
See Taro Pharmaceutical Industries Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$629.18 M
|
$572.95 M
|
$561.35 M
|
$548.97 M
|
$644.77 M
|
$669.89 M
|
$661.91 M
|
$879.39 M
|
$950.75 M
|
$862.94 M
|
| Cost of Revenue |
$324.20 M |
$304.63 M |
$268.23 M |
$252.31 M |
$245.04 M |
$224.17 M |
$198.41 M |
$208.14 M |
$171.79 M |
$186.36 M |
| Gross Profit |
$304.98 M |
$268.32 M |
$293.12 M |
$296.66 M |
$399.73 M |
$445.72 M |
$463.51 M |
$671.25 M |
$778.97 M |
$676.59 M |
| Gross Profit Ratio |
0.48 |
0.47 |
0.52 |
0.54 |
0.62 |
0.67 |
0.7 |
0.76 |
0.82 |
0.78 |
| Research and Development
Expenses |
$64.54 M
|
$52.24 M
|
$54.54 M
|
$60.15 M
|
$59.78 M
|
$63.24 M
|
$70.42 M
|
$70.64 M
|
$71.16 M
|
$65.51 M
|
| General & Administrative
Expenses |
$0.00
|
$85.09 M
|
$57.06 M
|
$52.81 M
|
$56.76 M
|
$83.44 M
|
$78.28 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$113.28 M
|
$56.62 M
|
$38.54 M
|
$36.66 M
|
$6.53 M
|
$9.91 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$218.94 M
|
$198.37 M
|
$113.68 M
|
$91.36 M
|
$93.41 M
|
$89.97 M
|
$88.20 M
|
$85.66 M
|
$92.37 M
|
$87.64 M
|
| Other Expenses |
$64.54 M |
$2.46 M |
$4.23 M |
$2.89 M |
$3.02 M |
$1.81 M |
$1.89 M |
$11.21 M |
$2.68 M |
$2.74 M |
| Operating Expenses |
$283.47 M |
$250.61 M |
$168.22 M |
$151.51 M |
$153.19 M |
$153.21 M |
$158.61 M |
$156.30 M |
$163.53 M |
$153.15 M |
| Cost And Expenses |
$607.67 M |
$555.24 M |
$436.44 M |
$403.82 M |
$398.23 M |
$377.38 M |
$357.02 M |
$364.44 M |
$335.31 M |
$339.51 M |
| Interest Income |
$56.19 M |
$22.10 M |
$8.19 M |
$20.17 M |
$33.65 M |
$33.54 M |
$19.93 M |
$14.47 M |
$12.60 M |
$9.68 M |
| Interest Expense |
$0.00 |
$1.25 M |
$1.65 M |
$1.36 M |
$725,000.00 |
$256,000.00 |
$304,000.00 |
$131,000.00 |
$473,000.00 |
$928,000.00 |
| Depreciation &
Amortization |
$31.09 M
|
$34.94 M
|
$25.92 M
|
$23.68 M
|
$6.55 M
|
$18.60 M
|
$16.50 M
|
$14.83 M
|
$14.85 M
|
$15.80 M
|
| EBITDA |
$38.40 M
|
$52.65 M
|
$164.89 M
|
-$413.78 M
|
$305.31 M
|
$282.13 M
|
$303.01 M
|
$509.61 M
|
$624.19 M
|
$493.40 M
|
| EBITDA Ratio |
0.08 |
0.09 |
0.37 |
1.33 |
0.39 |
0.42 |
0.54 |
0.58 |
0.66 |
0.57 |
| Operating Income Ratio
|
0.03
|
0.03
|
0.33
|
1.28
|
0.38
|
0.44
|
0.46
|
0.59
|
0.65
|
0.61
|
| Total Other
Income/Expenses Net |
$75.36 M
|
$20.50 M
|
-$47.06 M
|
-$536.22 M
|
$51.50 M
|
$60.66 M
|
-$10.64 M
|
$45.85 M
|
$22.35 M
|
$58.25 M
|
| Income Before Tax |
$82.67 M |
$38.21 M |
$77.86 M |
-$391.07 M |
$298.04 M |
$356.85 M |
$292.37 M |
$560.80 M |
$636.82 M |
$581.68 M |
| Income Before Tax Ratio
|
0.13
|
0.07
|
0.14
|
-0.71
|
0.46
|
0.53
|
0.44
|
0.64
|
0.67
|
0.67
|
| Income Tax Expense |
$28.80 M |
$12.77 M |
$19.59 M |
$9.67 M |
$53.49 M |
$74.73 M |
$81.95 M |
$103.78 M |
$95.31 M |
$96.06 M |
| Net Income |
$53.87 M |
$25.45 M |
$58.27 M |
-$400.74 M |
$244.24 M |
$281.78 M |
$211.15 M |
$456.36 M |
$540.93 M |
$484.26 M |
| Net Income Ratio |
0.09 |
0.04 |
0.1 |
-0.73 |
0.38 |
0.42 |
0.32 |
0.52 |
0.57 |
0.56 |
| EPS |
1.43 |
0.68 |
1.55 |
-10.49 |
6.35 |
7.23 |
5.26 |
11.05 |
12.62 |
11.31 |
| EPS Diluted |
1.43 |
0.68 |
1.55 |
-10.49 |
6.35 |
7.23 |
5.26 |
11.05 |
12.62 |
11.31 |
| Weighted Average Shares
Out |
$37.58 M
|
$37.58 M
|
$37.64 M
|
$38.21 M
|
$38.46 M
|
$38.99 M
|
$40.16 M
|
$41.30 M
|
$42.83 M
|
$42.83 M
|
| Weighted Average Shares
Out Diluted |
$37.58 M
|
$37.58 M
|
$37.64 M
|
$38.21 M
|
$38.46 M
|
$38.99 M
|
$40.16 M
|
$41.30 M
|
$42.83 M
|
$42.83 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
